Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06184113
Other study ID # 8.1-23/77-3; 02/013 AG
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date December 2023
Est. completion date December 2025

Study information

Verified date December 2023
Source Clinical Hospital Centre Zagreb
Contact Tomislav Kopjar, MD, PhD
Phone +385 (1) 2367 520
Email tomislav.kopjar@kbc-zagreb.hr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: The optimal antithrombotic strategy early after aortic valve replacement surgery with a biological valve remains controversial due to lack of high-quality evidence. Either oral anticoagulants or acetylsalicylic acid should be considered for the first three months. Hypo-attenuated leaflet thickening on cardiac compute tomography has been associated with latent bioprosthetic valve thrombosis and may be prevented with anticoagulation. The investigators hypothesize that anticoagulation with apixaban is superior to single antiplatelet therapy with acetylsalicylic acid in reduction of hypo-attenuated leaflet thickening of bioprosthetic valves after aortic valve replacement. Methods: In this prospective, open-label, randomized trial patients without an indication for oral anticoagulation undergoing isolated aortic valve replacement surgery with novel rapid-deployment bioprosthetic valves will be randomized. The treatment group will receive 5 mg of apixaban twice a day for the first three months and 100 mg of acetylsalicylic acid thereafter. The control group will have 100 mg of acetylsalicylic acid once a day indefinitely. After the three-month treatment period a contrast enhanced electrocardiogram-gated cardiac computed tomography will be performed to identify hypo-attenuated leaflet thickening of the bioprosthetic valve. The primary objective of the study is to assess possible superiority of the treatment group in the prevention of hypo-attenuated leaflet thickening three months after randomization. Secondary objective is to assess possible noninferiority for safety of apixaban-based strategy when compared to acetylsalicylic acid at three months. Discussion: Antithrombotic therapy after aortic valve replacement surgery is used to prevent valve thrombosis and systemic thromboembolism. Latent bioprosthetic valve thrombosis is a precursor of clinically significant prosthetic valve dysfunction or thromboembolic event. The hallmark feature of latent bioprosthetic valve thrombosis is hypo-attenuated leaflet thickening on cardiac computed tomography. Subclinical leaflet thrombosis occurs frequently in bioprosthetic aortic valves, more commonly in transcatheter than in surgical valves. There is no evidence on the effect of direct oral anticoagulants on the incidence of hypo-attenuated leaflet thickening after surgical aortic valve replacement with rapid deployment bioprostheses.


Recruitment information / eligibility

Status Recruiting
Enrollment 166
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria - Men and women aged 65 or older with aortic valve stenosis undergoing successful isolated first-time aortic valve replacement with a rapid deployment bioprosthetic valve - Signed informed consent to participate in the research Exclusion Criteria: - Indication for long-term use of anticoagulant therapy - Indication for dual antiplatelet therapy - Contraindication to anticoagulation or antiplatelet therapy - Inability to start the study drug within the planned randomization period - History of atrial fibrillation - Known hemorrhagic diathesis - Presence of other significant heart pathology - Prior open-heart surgery - Presence of liver failure or other coagulopathy - Aortic valve infective endocarditis - Severe renal failure - Allergy to iodine contrast

Study Design


Intervention

Procedure:
Aortic valve replacement surgery
Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.
Diagnostic Test:
Computed tomography
All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.
Echocardiography
All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.

Locations

Country Name City State
Croatia University Hospital Center Zagreb Zagreb

Sponsors (1)

Lead Sponsor Collaborator
Clinical Hospital Centre Zagreb

Country where clinical trial is conducted

Croatia, 

Outcome

Type Measure Description Time frame Safety issue
Other Rate of hypo-attenuated leaflet thickening Hypo-attenuated leaflet thickening is identified as increased thickness of one or more lea?ets of the bioprosthetic valve on contrast-enhanced electrocardiogram gated cardiac computed tomography. Grade 3 on a 4-tier semiquantitative grading scale describes more than 50% and less than 75% of leaflet involvement which will be considered significant. Grade 3 or higher will be considered significant. At the end of treatment at 3 months
Other Rate of reduced leaflet mobility Leaflet restriction caused by hypo-attenuated leaflet thickening can be described as reduced leaflet mobility. Using computed tomography, reduced leaflet motion will be assessed on short-axis reformatted images during systole and 4D volume rendering images. The extent can be described per lea?et, using a 4-tier grading scale in systole: (1) not present, (2) < 50% restriction in leaflet excursion, (3) =50% restriction in leaflet excursion and (4) immobile leaflet. Grade 3 or higher will be considered significant. At the end of treatment at 3 months
Other Proportion of patients in each NYHA functional class New York Heart Association functional classification of heart failure. Class I, no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II, slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III, marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV, symptoms of heart failure at rest. Any physical activity causes further discomfort. At the end of treatment at 3 months
Other Rates of bioprosthetic valve deterioration Stage 1 is described with morphological valve deterioration without significant hemodynamic changes. Stage 2 is characterized with moderate hemodynamic valve deterioration with an increase in mean transvalvular gradient =10 mmHg, and Stage 3 with severe hemodynamic valve deterioration with an increase in mean transvalvular gradient =20 mmHg. At the end of treatment at 3 months
Other Rate of VARC-3 bleeding events A descriptive classification scheme for VARC-3 bleeding, like the Bleeding Academic Research Consortium classification has been proposed. It includes 4-type bleeding scale: Type 1 (minor), Type 2 (major), Type 3 (life-threatening), and Type 4 (leading to death) bleeding. From enrolment to the end of treatment at 3 months
Other Proportion of patients with myocardial infarction Myocardial infarction with elevated biomarkers cTn values with at least symptoms of acute ischaemia, new ischaemic ECG changes, new pathologic Q-waves, imaging evidence of a new loss of viable myocardium or new wall motion abnormality, identification of a coronary thrombus by angiography or autopsy. From enrolment to the end of treatment at 3 months
Other Proportion of patients with stroke All stroke (ischaemic stroke, haemorrhagic stroke, or any stroke not otherwise specified) with signs and symptoms and with pathology or neuroimaging evidence of central nervous system infarction, or absence of other apparent causes. From enrolment to the end of treatment at 3 months
Other Proportion of patients that died All cause mortality. From enrolment to the end of treatment at 3 months
Primary Proportion of patients with hypo-attenuated leaflet thickening Hypo-attenuated leaflet thickening is identified as increased thickness of one or more lea?ets of the bioprosthetic valve on contrast-enhanced electrocardiogram gated cardiac computed tomography. Grade 3 on a 4-tier semiquantitative grading scale describes more than 50% and less than 75% of leaflet involvement. Grade 3 or higher of hypo-attenuated leaflet thickening of at least one bioprosthetic valve leaflet will be considered. At the end of treatment at 3 months
Secondary Proportion of patients with bleeding, thromboembolic event, or death The safety composite outcome will be comprised of all types of VARC-3 bleeding events, thromboembolic events (myocardial infarction and stroke), and death from any cause. From enrolment to the end of treatment at 3 months
See also
  Status Clinical Trial Phase
Completed NCT00774293 - Homoeopathic Association in Aortic Valve Surgery Phase 4
Completed NCT05107453 - Serratus Anterior Plane Block for Minimal Invasive Cardiac Surgery Phase 4
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Completed NCT01187329 - The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose N/A
Recruiting NCT05295628 - Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR N/A
Terminated NCT03680040 - RESILIENCE Trial: Evaluation of the Durability of Aortic Bioprostheses/Valves With RESILIA Tissue in Subjects Under 65
Recruiting NCT05539937 - Prospective Evaluation of the Quality of Life of Elderly Patients Undergoing Transfemoral Percutanous Aortic Valve Replacement (TAVI) for the Treatment of Severe Aortic Stenosis.
Recruiting NCT01522352 - Comparison Between Three Types of Stented Pericardial Aortic Valves N/A
Completed NCT01554709 - Safety and Performance Study of the CardioGard Cannula Phase 2/Phase 3
Suspended NCT04902053 - INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study
Completed NCT01404975 - TAVI Protocol - Paravertebral Block Study N/A
Recruiting NCT03889288 - Innovative Device for Pain Management by Millimeter Band Radiation: Electronic-Pain Killer N/A
Active, not recruiting NCT05404880 - INSPIRIS China PMCF Study
Recruiting NCT04652375 - Outcomes After Albumin vs Lactated Ringer's Solution in CABG and AVR Procedures N/A
Recruiting NCT06106451 - Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study) N/A
Completed NCT00860730 - PERCEVAL Pivotal Trial N/A
Active, not recruiting NCT00396760 - Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery Phase 3
Not yet recruiting NCT03603483 - Aortic Root Enlargement in Aortic Valve Replacement N/A
Terminated NCT01368666 - Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark N/A
Recruiting NCT03002272 - Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study